509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer

• Evan Hall,
• Carlo Bifulco,
• Aung Naing,
• Anthony Joshua,
• Georgina Long,
• Margaret Callahan,
• Brian Costello,
• Aaron Hansen,
• Brooke Shankles,
• Umut Ulge,
• Andrew Weickhardt

Affiliations

Evan Hall

6 Medicine, Hematology and Oncology, Stanford University, Stanford, California, USA

Carlo Bifulco

Providence Cancer Institute, Portland, Oregon, USA

Aung Naing

Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA

Anthony Joshua

3Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, NSW, Australia

Georgina Long

Melanoma Institute Australia, North Sydney, New South Wales, Australia

Margaret Callahan

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Brian Costello

3Mayo Clinic, Rochester, MN, USA

Aaron Hansen

6Princess Margaret Hospital, Toronto, Canada

Brooke Shankles

9Neoleukin Therapeutics, Inc., Seattle, WA, USA

Umut Ulge

9Neoleukin Therapeutics, Inc., Seattle, WA, USA

Andrew Weickhardt

10Olivia Newton-John Cancer Wellness and Res, Heidelberg, VT, Australia